Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 5/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9876139 | 0.83 | KDM5A (0.35) | KDM5AWDR5CPA1CPB2CDK5 | |
| SCHEMBL14421034 | 0.82 | KDM5A (0.33) | KDM5A | |
| SCHEMBL18199171 | 0.80 | KDM5A (0.33) | KDM5AWDR5 | |
| SCHEMBL16843172 | 0.78 | GCK (0.35) | KDM5ACPA1CPB2CDK5CDK5R1 | |
| SCHEMBL1420099 | 0.75 | CYP19A1 (0.41) | KDM5A | |
| SCHEMBL14037264 | 0.72 | CYP2C19 (0.36) | — | |
| SCHEMBL24642790 | 0.71 | CPA1 (0.30) | CPA1CPB2 | |
| SCHEMBL18857237 | 0.70 | — | — | |
| SCHEMBL20122344 | 0.69 | KDM5A (0.37) | KDM5A | |
| SCHEMBL18827409 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10487068-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2019-11-26 | — | — | US | disclosed |
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10487068-B2 | Pyridazine derivatives as RORc modulators | RORC, RORB, RORA | KDM5A 1623/4885WDR5 1283/4885CPA1 3929/4885 |
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | KDM5A 1623/4885WDR5 1283/4885CPA1 3929/4885 |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | KDM5A 1952/4885WDR5 1329/4885CPA1 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.